Literature DB >> 15385516

Nucleic acid vaccination with Schistosoma mansoni antioxidant enzyme cytosolic superoxide dismutase and the structural protein filamin confers protection against the adult worm stage.

Rosemary M Cook1, Claudia Carvalho-Queiroz, Gregory Wilding, Philip T LoVerde.   

Abstract

Schistosomiasis remains a worldwide endemic cause of chronic and debilitating illness. There are two paradigms that exist in schistosome immunology. The first is that the schistosomule stages are the most susceptible to immune killing, and the second is that the adult stage, through evolution of defense mechanisms, can survive in the hostile host environment. One mechanism that seems to aid the adult worm in evading immune killing is the expression of antioxidant enzymes to neutralize the effects of reactive oxygen and nitrogen species. Here, we challenge one paradigm by targeting adult Schistosoma mansoni worms for immune elimination in an experimental mouse model using two S. mansoni antioxidants, cytosolic superoxide dismutase (SmCT-SOD) and glutathione peroxidase (SmGPX), and a partial coding sequence for a structural protein, filamin, as DNA vaccine candidates. DNA vaccination with SmCT-SOD induced a mean of 39% protection, filamin induced a mean of 50% protection, and SmGPX induced no protection compared to controls following challenge with adult worms by surgical transfer. B- and T-cell responses were analyzed in an attempt to define the protective immune mechanism(s) involved in adult worm killing. SmCT-SOD-immunized mice presented with a T1 response, and filamin-immunized mice showed a mixed T1-T2 response. We provide evidence for natural boosting after vaccination. Our results demonstrate that adult worms can be targeted for immune elimination through vaccination. This represents an advance in schistosome vaccinology and allows for the development of a therapeutic as well as a prophylactic vaccine.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15385516      PMCID: PMC517585          DOI: 10.1128/IAI.72.10.6112-6124.2004

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  53 in total

1.  Expression and characterization of glutathione peroxidase activity in the human blood fluke Schistosoma mansoni.

Authors:  H Mei; A Thakur; J Schwartz; P T Lo Verde
Journal:  Infect Immun       Date:  1996-10       Impact factor: 3.441

2.  Transfer of Schistosoma mansoni into the mesenteric veins of hamsters.

Authors:  D Cioli
Journal:  Int J Parasitol       Date:  1976-08       Impact factor: 3.981

3.  Antioxidant systems in Schistosoma mansoni: correlation between susceptibility to oxidant killing and the levels of scavengers of hydrogen peroxide and oxygen free radicals.

Authors:  G M Mkoji; J M Smith; R K Prichard
Journal:  Int J Parasitol       Date:  1988-07       Impact factor: 3.981

4.  Schistosoma mansoni: levels of antioxidants and resistance to oxidants increase during development.

Authors:  B Nare; J M Smith; R K Prichard
Journal:  Exp Parasitol       Date:  1990-05       Impact factor: 2.011

Review 5.  Mechanisms of immune evasion in schistosomiasis.

Authors:  E J Pearce; A Sher
Journal:  Contrib Microbiol Immunol       Date:  1987

6.  Schistosoma mansoni: cloning the gene encoding glutathione peroxidase.

Authors:  H Mei; P T LoVerde
Journal:  Exp Parasitol       Date:  1995-03       Impact factor: 2.011

7.  Fas ligand-expressing B-1a lymphocytes mediate CD4(+)-T-cell apoptosis during schistosomal infection: induction by interleukin 4 (IL-4) and IL-10.

Authors:  Steven K Lundy; Dov L Boros
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

8.  Post lung-stage schistosomula of Schistosoma mansoni exhibit transient susceptibility to macrophage-mediated cytotoxicity in vitro that may relate to late phase killing in vivo.

Authors:  E J Pearce; S L James
Journal:  Parasite Immunol       Date:  1986-09       Impact factor: 2.280

9.  Interleukin 10 inhibits macrophage microbicidal activity by blocking the endogenous production of tumor necrosis factor alpha required as a costimulatory factor for interferon gamma-induced activation.

Authors:  I P Oswald; T A Wynn; A Sher; S L James
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

10.  The global epidemiological situation of schistosomiasis and new approaches to control and research.

Authors:  D Engels; L Chitsulo; A Montresor; L Savioli
Journal:  Acta Trop       Date:  2002-05       Impact factor: 3.112

View more
  22 in total

1.  Specific humoral response of hosts with variable schistosomiasis susceptibility.

Authors:  Patrick Driguez; Hamish E G McWilliam; Soraya Gaze; David Piedrafita; Mark S Pearson; Rie Nakajima; Mary Duke; Angela Trieu; Denise L Doolan; Fernanda C Cardoso; Algis Jasinskas; Geoffrey N Gobert; Philip L Felgner; Alex Loukas; Els Meeusen; Donald P McManus
Journal:  Immunol Cell Biol       Date:  2015-06-05       Impact factor: 5.126

2.  Partial immunity to Fasciola hepatica in mice after vaccination with FhSAP2 delivered as recombinant protein or DNA construct.

Authors:  Ana M Espino; Adelaida Morales; Bonnibel Delgado; Francheska M Rivera; Olgary Figueroa; Erick Suárez
Journal:  Ethn Dis       Date:  2010       Impact factor: 1.847

Review 3.  The redox biology of schistosome parasites and applications for drug development.

Authors:  Hsin-Hung Huang; Coraline Rigouin; David L Williams
Journal:  Curr Pharm Des       Date:  2012       Impact factor: 3.116

4.  Use of an Sm-p80-based therapeutic vaccine to kill established adult schistosome parasites in chronically infected baboons.

Authors:  Souvik Karmakar; Weidong Zhang; Gul Ahmad; Workineh Torben; Mayeen U Alam; Loc Le; Raymond T Damian; Roman F Wolf; Gary L White; David W Carey; Darrick Carter; Steven G Reed; Afzal A Siddiqui
Journal:  J Infect Dis       Date:  2014-01-16       Impact factor: 5.226

5.  Imaging schistosomes in vivo.

Authors:  Greice Krautz-Peterson; David Ndegwa; Kristine Vasquez; Houari Korideck; Jun Zhang; Jeffrey D Peterson; Patrick J Skelly
Journal:  FASEB J       Date:  2009-04-03       Impact factor: 5.191

6.  DNA vaccination by electroporation and boosting with recombinant proteins enhances the efficacy of DNA vaccines for Schistosomiasis japonica.

Authors:  Yang Dai; Yinchang Zhu; Donald A Harn; Xiaoting Wang; Jianxia Tang; Song Zhao; Fei Lu; Xiaohong Guan
Journal:  Clin Vaccine Immunol       Date:  2009-10-07

7.  Functional expression and characterization of a cytosolic copper/zinc-superoxide dismutase of Spirometra erinacei.

Authors:  Ai-Hua Li; Byoung-Kuk Na; Sung-Kyu Ahn; Shin-Hyeong Cho; Jhang-Ho Pak; Yun-Kyu Park; Tong-Soo Kim
Journal:  Parasitol Res       Date:  2010-02       Impact factor: 2.289

Review 8.  Experimental vaccines in animal models for schistosomiasis.

Authors:  Afzal A Siddiqui; Gul Ahmad; Raymond T Damian; Ronald C Kennedy
Journal:  Parasitol Res       Date:  2008-02-08       Impact factor: 2.289

Review 9.  Computational vaccinology: an important strategy to discover new potential S. mansoni vaccine candidates.

Authors:  Carina S Pinheiro; Vicente P Martins; Natan R G Assis; Bárbara C P Figueiredo; Suellen B Morais; Vasco Azevedo; Sergio C Oliveira
Journal:  J Biomed Biotechnol       Date:  2011-10-15

10.  Vaccination with enzymatically cleaved GPI-anchored proteins from Schistosoma mansoni induces protection against challenge infection.

Authors:  Vicente P Martins; Carina S Pinheiro; Barbara C P Figueiredo; Natan R G Assis; Suellen B Morais; Marcelo V Caliari; Vasco Azevedo; William Castro-Borges; R Alan Wilson; Sergio C Oliveira
Journal:  Clin Dev Immunol       Date:  2012-08-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.